In the matter of Norris Medicines Ltd.

Page 1 of 2
WTM/RKA/OIAE/111/2014

BEFORE THE SECURITIES AND EXCHANGE BOARD OF INDIA

ORDER

Under section 11B of the Securities and Exchange Board of India Act, 1992 in the matter of
Norris Medicines Ltd.

In respect of Norris Medicines Ltd. and its directors, namely, Mr. Sanjiv Kumar Shah, Mr.
Navnit Jethabhai Patel, Mr. Vimal Dhirendra Shah and Mr. Sureshbhai Gulabchand Patel.
______________________________________________________________________________

1. Norris Medicines Ltd. (hereinafter referred to as 'Norris' or the company) is a company
incorporated under the Companies Act, 1956 having its registered office at Vikram Apartments,
Plot No 7, Chakravarti Ashok Road, Kandivali (E), Mumbai 400 101, Maharashtra. The shares
of the company are listed on Bombay Stock Exchange Ltd. (BSE), Delhi Stock Exchange (DSE)
and Ahmedabad Stock Exchange Limited (ASE). It was observed from the website of Ministry
of Corporate Affairs that there are four directors of the company, namely, Mr. Sanjiv Kumar
Shah, Mr. Navnit Jethabhai Patel, Mr. Vimal Dhirendra Shah, and Mr. Sureshbhai Gulabchand
Patel (hereinafter collectively referred to as "directors").

2. SEBI vide circular no. CIR/OIAE/1/2012 dated August 13, 2012 directed all companies whose
securities are listed on stock exchanges to obtain SCORES authentication by September 14,
2012. However, certain companies including Norris did not obtain SCORES authentication
within the time period specified in the aforementioned circular. Therefore, a public notice was
issued on January 13, 2013, advising inter alia, the company to obtain SCORES authentication
within seven days from the date of the advertisement, failing which SEBI would be constrained
to initiate appropriate enforcement actions. The company obtained SCORES authentication on
January 21, 2013 but, failed to redress the five pending complaints against the company.

3. Since Norris failed to redress the investor grievances, SEBI issued Show Cause Notices (SCNs)
dated March 28, 2013 and April 26, 2013, to Norris and its directors, respectively, calling upon
then to show cause as to why suitable directions including the direction to restrain them from
accessing the securities market for a specified period should not be issued under section 11B of
the SEBI Act.

Brought to you by http://StockViz.biz

In the matter of Norris Medicines Ltd. Page 2 of 2
4. In the meantime, the company vide its letter dated April 24, 2013 submitted that on verifying the
status of SCORES complaints, it had come to know that SCN has been issued against it in
relation to alleged non redressal of investor grievances. The company further submitted that it
had not yet received the SCN and requested for a copy of the SCN. Further, vide an email dated
April 25, 2013 the company providing a new address i.e. Norris Medicines Ltd., Plot no. 801/P,
901/4-5, GIDC Estate, Ankleshwar, Gujarat 393002 for further correspondence. Accordingly,
SEBI vide its letter date April 26, 2013 forwarded a copy of the SCN dated March 28, 2013 to
the company.

5. Subsequently, SEBI has observed that the company has resolved all the investor complaints
referred in the SCNs and there are no further investor grievances pending on SCORES against
it.

6. Considering the facts and circumstances of the case, I am of the view that there is no need to
pass any direction under section 11B of the SEBI Act against Norris Medicines Ltd. and its
directors, as contemplated in the SCNs issued to them. However, the noticees are advised to
take utmost care and be vigilant in future, in respect of redressal of investor grievances. The
SCNs are accordingly disposed of.




Date: September, 22
nd
2014 RAJEEV KUMAR AGARWAL
Place: Mumbai WHOLE TIME MEMBER
SECURITIES AND EXCHANGE BOARD OF INDIA

Brought to you by http://StockViz.biz